An Evolution of Healing
An industry-leading biotechnology company, we specialize in developing and manufacturing advanced biomaterials for bone and soft tissue regeneration. With a relentless commitment to improving patient outcomes and revolutionizing the field of synthetic grafts, NovaBone products have emerged as a global visionary in developing innovative bone substitutes.
Offering the first Bioglass product to the medical community and leveraging the osteostimulative properties of 45S5 bioactive glass material, we not only foster bone tissue regeneration but also set a benchmark for future advancements in bone healing solutions.
A Legacy of Innovation: The Bioglass Journey
In the late 1960s, a groundbreaking discovery by Dr. Larry Hench transformed medical science. It all started at the University of Florida in Gainesville, mere miles from NovaBone's future offices. Dr. Hench's research on the biological application of glass had reached a breakthough, giving birth to 45S5 Bioglass. It was the first material of its kind to bond with living bone and stimulate bone regeneration. This remarkable invention not only paved the way for modern biomaterials but also set the foundation for the next generation of bone regeneration technologies.
At NovaBone, we are proud to continue this legacy of innovation. Our employee, Jipin Zhong, PhD, stands as a testament to our deep connection with 45S5 Bioglass' origins. Having studied directly under Dr. Larry Hench himself, Zhong embodies the bridge between foundational research and our cutting-edge applications in bone regeneration.
Our Commitment to Healing
Our products are designed with a deep understanding of the science of bone healing, leveraging the bioactive properties of Bioglass to support the body's natural healing processes. At NovaBone, we are not just creating products; we are crafting solutions that embody the spirit of innovation and commitment to improving patient outcomes.
Today, our company offers the broadest portfolio of regenerative grafting devices including bone formation products, as well as products that repair and remodel tissue. NovaBone’s bioactive bone graft devices have been used for over two decades in millions of clinical applications with unparalleled success validating the safety and efficacy of our technology.
Discover how our Bioglass-based products are setting new standards in regenerative medicine. With a foundation rooted in groundbreaking science and a future focused on innovation, NovaBone is at the forefront of healing technologies. Join us in shaping the future of bone regeneration.
Our History
2023
Wound Matrix
Received FDA clearance for Wound Matrix. NovaBone under new leadership continues with the purpose of positively impacting lives. Launched the foot and ankle-specific syringe delivery system.
2023
2020
Halma
NovaBone joined forces with Halma PLC, a distinguished member of the FTSE 100 global group of life-saving technology companies.
2017
NovaBone IRM
Received FDA clearance for the Irrigation Resistance Matrix product and launched two versions of the NovaBone IRM.
2017
2015
Dental Collagen
Received FDA clearance for dental collagen wound dressings (plugs and tapes) and started manufacturing private-label wound dressings for various tier-one dental brands.
2014
Alachua, FL
NovaBone Products moved into a new 29,000 sq. ft. facility in Alachua, Florida significantly expanding its manufacturing capacity.
2014
2014
MacroFORM and Bioactive Strip
Received FDA clearance for the first collagen bioactive glass composite products and launched NovaBone MacroFORM and Bioactive Strip.
2012
Collagen-based Composite
NovaBone expanded its R&D and manufacturing capabilities to widen its bone graft portfolio to collagen-based composite products.
2012
2011
Putty Cartridge Delivery System
Launched industry-first MIS putty delivery system.
2009
Porous Granules
The Company broadened the bone graft portfolio and launched the morselized porous granules in vials and syringes.
2009
2006
NovaBone Putty
Received FDA clearance for second-generation bioactive synthetic putty bone graft substitute and launched NovaBone Putty.
2005
Particulate Bone Graft
Received FDA clearance for the second- generation resorbable and bioactive synthetic particulate bone graft substitute.
2005
2002
NovaBone Products, LLC
NovaBone Products, LLC was established with the purpose of developing differentiated synthetic biomaterials leveraging proprietary bioactive glass technology. Received FDA clearance for the first- generation resorbable particulate bone graft substitute.
